You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 11,065,224


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,065,224
Title:Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):Megret Claire, Guillard Herve, Dubuisson Jean-Francois
Assignee:Flamel Ireland Limited
Application Number:US16527633
Patent Claims: 1. A pharmaceutical composition that releases gamma-hydroxybutyrate in the blood stream of a human subject , wherein the composition is designed to be administered only once per night , wherein the composition is effective to induce sleep for at least six consecutive hours , and wherein upon administration to a human subject approximately two hours after a standardized evening meal and{'figref': {'@idref': 'DRAWINGS', 'FIG. 12'}, 'at a dose equivalent to 4.5 g or 6.0 g of sodium oxybate, the composition yields a plasma concentration versus time curve bioequivalent to the plasma concentration versus time curve depicted in for the corresponding dose;'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 13'}, 'at a dose equivalent to 4.5 g, 6.0 g, or 7.5 g of sodium oxybate, the composition yields a plasma concentration versus time curve bioequivalent to the plasma concentration versus time curve depicted in for the corresponding dose; or'}{'figref': {'@idref': 'DRAWINGS', 'FIG. 90'}, 'at a dose equivalent to 4.5 g, 7.5 g, or 9.0 g of sodium oxybate, the composition yields a plasma concentration versus time curve bioequivalent to the plasma concentration versus time curve depicted in for the corresponding dose.'}2. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .3. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .4. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile between the minimum and maximum values depicted in and .5. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile between the minimum and maximum values depicted in and .6. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile between the minimum and maximum values depicted in and .7. The pharmaceutical composition of claim 1 , wherein the composition is defined based on the concentration of gamma-hydroxybutyrate in the blood stream 8 hours after administration to a patient claim 1 , and further wherein a dose equivalent to a 4.5 g dose of sodium oxybate achieves a mean Cof from 4.7 to 9.0 microgram/mL.8. The pharmaceutical composition of claim 1 , wherein the composition is defined based on the concentration of gamma-hydroxybutyrate in the blood stream 8 hours after administration to a patient claim 1 , and further wherein a dose equivalent to a 4.5 g dose of sodium oxybate achieves a mean Cof from 3.5 to 4.7 microgram/mL.9. The pharmaceutical composition of claim 1 , wherein the composition is defined based on the concentration of gamma-hydroxybutyrate in the blood stream 8 hours after administration to a patient claim 1 , and further wherein a dose equivalent to a 6.0 g dose of sodium oxybate achieves a mean Cof from 6.3 to 16.7 microgram/mL.10. The pharmaceutical composition of claim 1 , wherein the composition is defined based on the concentration of gamma-hydroxybutyrate in the blood stream 8 hours after administration to a patient claim 1 , and further wherein a dose equivalent to a 6.0 g dose of sodium oxybate achieves a mean Cof from 7.3 to 15.4 microgram/mL.11. The pharmaceutical composition of claim 1 , wherein the composition is defined based on the concentration of gamma-hydroxybutyrate in the blood stream 8 hours after administration to a patient claim 1 , and further wherein a dose equivalent to a 7.5 g dose of sodium oxybate achieves a mean Cof from 13.0 to 40.3 microgram/mL.12. The pharmaceutical composition of claim 1 , wherein the composition is defined based on the concentration of gamma-hydroxybutyrate in the blood stream 8 hours after administration to a patient claim 1 , and further wherein a dose equivalent to a 7.5 g dose of sodium oxybate achieves a mean Cof from 24.7 to 37.2 microgram/mL.13. The pharmaceutical composition of claim 1 , wherein the composition is defined based on the time required to reach maximum blood concentration of gamma-hydroxybutyrate to a patient claim 1 , and further achieves a median Tof 1.25 to 3.25 hours when administered once approximately two hours after a standardized evening meal.14. The pharmaceutical composition of claim 1 , wherein the composition is defined based on the time required to reach maximum blood concentration of gamma-hydroxybutyrate to a patient claim 1 , and further achieves a median Tof 0.5 to 3.25 hours when administered once approximately two hours after a standardized evening meal.15. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile bioequivalent to the dissolution profile depicted in .16. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile bioequivalent to the dissolution profile depicted in .17. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile bioequivalent to the dissolution profile depicted in .18. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile bioequivalent to the dissolution profile depicted in .19. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .20. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .21. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .22. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile bioequivalent to the dissolution profile depicted in .23. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .24. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .25. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .26. The pharmaceutical composition of claim 1 , wherein the composition yields a dissolution profile bioequivalent to the dissolution profile depicted in .27. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .28. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .29. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .30. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .31. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .32. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .33. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .34. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .35. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .36. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .37. The pharmaceutical composition of claim 1 , wherein the composition yields dissolution profiles bioequivalent to the dissolution profiles depicted in and .38. The pharmaceutical composition of claim 1 , wherein the composition is effective to induce sleep for at least eight consecutive hours.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.